BioRem Inc. (CVE:BRM – Get Free Report) shares reached a new 52-week high on Wednesday. The stock traded as high as C$4.50 and last traded at C$4.50, with a volume of 20,761 shares changing hands. The stock had previously closed at C$4.50.
BioRem Price Performance
The firm has a market cap of C$72.93 million, a PE ratio of 13.39 and a beta of 0.78. The company has a current ratio of 2.37, a quick ratio of 1.08 and a debt-to-equity ratio of 11.30. The stock has a 50 day simple moving average of C$3.65 and a 200-day simple moving average of C$3.16.
Insider Buying and Selling at BioRem
In related news, Director Derek Webb sold 28,700 shares of BioRem stock in a transaction on Monday, August 24th. The shares were sold at an average price of C$3.82, for a total transaction of C$109,634.00. Following the sale, the director owned 362,370 shares of the company’s stock, valued at C$1,384,253.40. The trade was a 7.34% decrease in their position. 1.90% of the stock is owned by insiders.
BioRem Company Profile
BioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems.
Recommended Stories
- Five stocks we like better than BioRem
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for BioRem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRem and related companies with MarketBeat.com's FREE daily email newsletter.
